Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression

Mult Scler. 2020 Sep;26(10):1268-1269. doi: 10.1177/1352458520926459. Epub 2020 May 28.

Authors

Affiliations

¹ Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.
² University of Milan, Milan, Italy.

PMID: 32463329
DOI: 10.1177/1352458520926459

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Alemtuzumab / adverse effects*
COVID-19
Coronavirus Infections / complications
Coronavirus Infections / immunology*
Coronavirus Infections / physiopathology
Female
Humans
Immunosuppressive Agents / adverse effects*
Leukopenia / chemically induced
Leukopenia / immunology
Lymphopenia / chemically induced*
Lymphopenia / immunology
Multiple Sclerosis, Relapsing-Remitting / complications
Multiple Sclerosis, Relapsing-Remitting / drug therapy*
Neutropenia / chemically induced*
Neutropenia / immunology
Pandemics
Pneumonia, Viral / complications
Pneumonia, Viral / immunology*
Pneumonia, Viral / physiopathology
Severity of Illness Index

Substances

Immunosuppressive Agents
Alemtuzumab